Association between Anemia and Multiple Sclerosis

Koudriavtseva, Tatiana; Renna, Rosaria; Plantone, Domenico; Mandoj, Chiara; Piattella, Maria Cristina; Giannarelli, Diana

doi:10.1159/000381212

Cited by 13 publications

(19 citation statements)

References 25 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Одним из наиболее крупных исследований [2] по изучению распространенности анемии при РС является ретроспективное кросс-секционное исследование случай-контроль, проведенное в Италии и включившее 187 пациентов с РС. Авторами было вы-1 World Health Organization.…”

Section: распространенность анемии при рсunclassified

“…анемия носила микроцитарный характер. Авторы не обнаружили достоверно значимой связи между наличием анемии при РС и полом, типом течения и продолжительностью заболевания, оценкой по шкале EDSS [2]. Несмотря на то что анемия является одним из побочных эффектов иммуномодулирующей терапии РС [9], в исследовании не показано достоверной связи между наличием и видом терапии РС и частотой анемии.…”

Section: распространенность анемии при рсunclassified

“…Имеются описания развившихся у пациентов с РС лекарственно-индуцированных анемий, вызван-ных интерферонами-β, натализумабом, финголимодом, митоксантроном: гемолитической анемии [19][20][21][22][23], гипорегенеративной и апластической [24,25]. В средиземноморском регионе у пациентов с РС может выявляться серповидно-клеточная анемия [2]. Тем не менее случаи пернициозной, гемолитической, апластической и наследственных анемий при РС являются единичными.…”

Section: типы анемий у пациентов с рсunclassified

“…Тем не менее случаи пернициозной, гемолитической, апластической и наследственных анемий при РС являются единичными. Большая часть анемий при РС, как и в общей популяции, являются железодефицитными анемиями (ЖДА) либо анемиями хронических заболеваний (АХЗ) [2].…”

Section: типы анемий у пациентов с рсunclassified

“…Работ, посвященных частоте выявления АХЗ у пациентов с РС, найдено не было; однако с теоретических позиций развитие этого варианта анемий у больных с РС представляется весьма вероятным [2].…”

Section: типы анемий у пациентов с рсunclassified

See 4 more Smart Citations

Anemia and dysregulation of iron metabolism in multiple sclerosis

Белова

Solovieva

Boyko

2018

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Anemia is one of the common diseases comorbid with multiple sclerosis (MS). This article reviews the prevalence and types of anemia in MS patients. It has been shown that anemia is often accompanied by a decrease in serum iron level. The authors present the data on iron metabolism in patients with MS and MRI findings concerning deposits of iron in the gray matter of the brain. The causal relationship between abnormalities in iron metabolism and MS remains unclear; this study allows to approach the understanding of the MS pathogenesis and to increase the efficacy of therapy for this disease.

show abstract

Section: распространенность анемии при рсunclassified

Section: типы анемий у пациентов с рсunclassified

See 3 more Smart Citations

Anemia and dysregulation of iron metabolism in multiple sclerosis

Белова

Solovieva

Boyko

2018

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

show abstract

A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications

2020

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system which is associated with numerous comorbidities. These include cardiovascular disease, psychiatric and neurologic disturbances, restless leg syndrome, migraine, cancer, autoimmune diseases, and metabolic disorders. Comorbid disease is an important consideration for clinicians treating patients with MS; early presentation of comorbidities can obscure or delay MS diagnosis, as well as significantly impacting the disease course. Improved understanding of comorbidities and their emergence in MS populations is important for improving the quality of life and optimizing treatment for patients. Therefore, we evaluated published studies reporting epidemiologic data on comorbidities and their associated impact on disease progression in patients with MS (PwMS). The prevalence of neurologic, cardiovascular, metabolic, and autoimmune comorbidities was elevated in PwMS in general, and furthermore, this adversely affected a broad range of outcomes. Compared with PwMS, cancer rates in people without MS or the general population were lower, which should prompt further studies into the mechanisms of both diseases. Studies were under-represented in many regions owing to the latitudinal gradient of MS and possible underfunding of studies.

show abstract

Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis

Taylor

Winzenberg

et al. 2020

J Neurol

View full text Add to dashboard Cite

Background:Little is known about the change in prevalence of comorbidities during the disease course of people with multiple sclerosis (MS) and whether the prevalences vary by MS onset-type.Objective: To calculate the change in prevalence of comorbidities between symptom onset and the time of study, to compare the prevalences of comorbidities with those in the Australian population at the time of study and to examine onset-type differences.Methods: Comorbidity data from 1,518 participants of the Australian MS Longitudinal Study and Australian population comparator data (2014-15 National Health Survey) were used. The change in prevalence between time points and prevalence ratios (PR) at the time of study (crude, age-and-sex adjusted, and stratified by onset-type) were calculated.Results: Comorbidities were common, and those with the largest increases in prevalence between MS symptom onset and the time of study were depression (+26.9%), anxiety (+23.1%), hypertension (+21.9%), elevated cholesterol (+16.3%), osteoarthritis (+17.1%), eye diseases (+11.6%), osteoporosis (+10.9%) and cancer (+10.3%). Compared to the general population and after age-and-sex adjustment, participants had a significantly higher prevalence for 14/19 comorbidities at the time of study. The associations were strongest for anaemia, cancer (both PR>4.00), anxiety, depression, migraine (all PR>3.00), psoriasis and epilepsy (both PR>2.00). No significant differences were seen by onset-type. Conclusion:Comorbidities are common at MS symptom onset and increase with MS duration.Having MS may thus contribute to accrual of comorbidities. This emphasises the importance of optimal screening for and management of comorbidities in early MS and throughout the disease course.

show abstract

Association between Anemia and Multiple Sclerosis

Cited by 13 publications

References 25 publications

Anemia and dysregulation of iron metabolism in multiple sclerosis

Anemia and dysregulation of iron metabolism in multiple sclerosis

A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications

Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis

Contact Info

Product

Resources

About